![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/10\/20261021_ROR2_AML_Technology_and_Modalities-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Shenzhen University and collaborators<\/p>\n Event Type<\/strong><\/p>\n Peer-Reviewed Preclinical Publication (Cancer Gene Therapy)<\/p>\n Modality<\/strong><\/p>\n CAR-T cell therapy (anti-ROR2)<\/p>\n Asset<\/strong><\/p>\n Anti-ROR2 CAR T construct (preclinical)<\/p>\n Target<\/strong><\/p>\n ROR2<\/p>\n Disease Area<\/strong><\/p>\n Adverse-risk acute myeloid leukemia<\/p>\n An online-first peer-reviewed Cancer Gene Therapy paper identifies surface ROR2 on a subset of adverse-risk AML, including stem-like cells, and reports selective killing with an anti-ROR2 CAR T construct. The central translational proposition is a myeloid target with a wider leukemia-versus-normal-HSC window.<\/p>\n Using a new cross-reactive B16 antibody, the authors examined primary AML and normal marrow and engineered a ROR2 CAR. Fifteen ROR2-positive AML samples had detectable ROR2 on phenotypic CD34+CD38\u2212 leukemia stem cells; normal HSCs from five donors had markedly lower signal. CAR T cells killed ROR2-positive primary AML ex vivo, spared tested normal marrow, and reduced leukemia including stem-like cells in immunodeficient mouse xenografts. The article appeared online 21 October 2026; no clinical treatment or issue-date outcome is reported.<\/p>\n AML CAR-T development is constrained by targets shared with normal myeloid progenitors. ROR2 offers a plausible antigen-selection approach, particularly in adverse-risk biology, and the study links protein expression to functional cytotoxicity rather than relying only on bulk RNA. A high-affinity binder and human\/mouse reactivity help test pharmacology and tissue expression.<\/p>\n The rival explanation is that sparse normal-tissue sampling and immunodeficient mice understate on-target\/off-tissue injury. Physiologic stress may induce ROR2 in normal compartments; heterogeneous AML clones may escape; CD34+CD38\u2212 is an imperfect functional LSC marker. The five-donor HSC dataset is too small to define a safe therapeutic window. Required next experiments include normal HSC colony and serial engraftment assays, broad tissue binding, low-antigen-density thresholds, and patient-derived models spanning ROR2-low subclones.<\/p>\n AML is a clonal myeloid malignancy in which relapse may be sustained by stem-like cells. ROR2 is a noncanonical Wnt receptor with low expression in many adult tissues but detectable expression in some cancers. The engineered CAR redirects T cells to its surface epitope.<\/p>\n Inference: this is a target-validation signal, not a treatment-ready platform. The partnering opportunity depends on proving antigen exclusivity and persistence under realistic human marrow conditions.<\/p>\n Signal Importance: 4 of 5. Signal Direction: Positive, preclinical. Confidence in Facts: High. Confidence in Interpretation: Moderate\u2013Low. The direction score describes the evidence at this stage. It does not imply clinical approval, treatment readiness or commercial outcome.<\/p>\n","protected":false},"excerpt":{"rendered":" An online-first peer-reviewed Cancer Gene Therapy paper identifies surface ROR2 on a subset of adverse-risk AML, including stem-like cells, and reports selective killing with an anti-ROR2 CAR T construct. The central translational proposition is…<\/p>\n","protected":false},"author":1,"featured_media":3819,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,583,1155,1154,1153],"class_list":["post-3817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-car-t","tag-leukemia-stem-cells","tag-ror2","tag-shenzhen-university"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3817"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3817\/revisions"}],"predecessor-version":[{"id":3836,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3817\/revisions\/3836"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3819"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n